To investigate the mechanism by which angiotensin-converting enzyme (ACE) inhibition attenuates atherogenesis, we have studied the effects of a nonsulfhydryl ACE inhibitor, enalapril, and an angiotensin receptor antagonist, SC-51316, in cholesterol-fed rabbits. After 3 mo of enalapril treatment (10 mg/kg per d, p.o.) the percent plaque areas in the thoracic aortas of treated animals were significantly reduced (controls: 86.8±3.5%; treated: 31.1±8%, P < 0.001). Aortic cholesterol content was also reduced (controls: 31.4±3.2 mg/g tissue; treated: 7.4±1.8 mg/g, P < 0.001). Enalapril had no significant effect on plasma lipid levels or conscious blood pressure. In a second study, the angiotensin II receptor antagonist SC-51316 was administered at a dose equivalent to enalapril at blocking angiotensin pressor effects in vivo (30 mg/kg per d, p.o.). Evaluation after 3 mo indicated no significant attenuation of aortic atherosclerosis. These results demonstrate that: (a) enalapril attenuates atherogenesis without affecting either blood pressure or plasma lipid levels; (b) antioxidant activity, found with sulfhydryl-containing ACE inhibitors, is not necessary for reducing plaque formation; and (c) the attenuation of atherogenesis by ACE inhibition may not be due to blockade of the renin-angiotensin system. Alternatively, one must consider the multiple effects of ACE inhibition on other hormone systems, such as bradykinin, or the possibility that alternate angiotensin II receptors may be involved in atherosclerosis. (J. Clin.
Introduction
The importance ofhigh blood pressure as a risk factor for developing cardiovascular disease is well established. However, it has been found that drug therapies that successfully reduce blood pressure and the incidence of stroke do not necessarily reduce the morbidity and mortality associated with coronary artery disease ( 1, 2) . These findings appear to indicate a multifactorial relationship between hypertension and atherosclerosis, suggesting that additional mechanisms, other than in-creased systemic blood pressure, contribute to the accelerated atherosclerosis associated with hypertension. Increased plasma or tissue levels of vasoactive hormones, such as angiotensin II, may play a role in such mechanisms (3) . This possibility is further supported by a report showing that, independent of other risk factors and within a narrow range ofblood pressures, a high renin profile is clearly associated with an increased risk of myocardial infarction but not stroke (4) .
Recently, two studies reported that the sulfhydryl-containing angiotensin-converting enzyme (ACE) ' inhibitor captopril can reduce the progression of atherosclerosis: after 9 mo in Watanabe heritable hyperlipidemic rabbits (5) and after 6 mo in cholesterol-fed cynomolgus monkeys (6) . These data suggest that the renin-angiotensin system (RAS) may play a direct role in plaque formation, possibly through angiotensin II stimulation ofcell proliferation (7) . However, although both ofthese studies used normotensive animals, captopril treatment also caused a significant reduction in blood pressure (5, 6) . Such an effect could account for the reduction in atherosclerosis, since it has been shown that even in normotensive populations those with the lowest pressures are at a reduced risk for cardiovascular disease (8), while in cholesterol-fed animals, ligation ofvessels to reduce pressure resulted in a significant reduction in lesion development (9, 10). In addition, captopril contains a sulfhydryl moiety that could act as an antioxidant (5, 6) , inhibiting the formation of oxidation products that may be involved in atherogenesis (1 1, 12) . It should also be noted that ACE inhibitors can affect other hormone systems, including enkephalins, substance P, kinins, and prostaglandins, which may also have effects on atherogenesis ( 1 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Thus the mechanism for the effect ofcaptopril on atherosclerosis remains unclear.
In an effort to differentiate among some of the possible mechanisms involved in the beneficial effects of ACE inhibition on atherogenesis, we have studied the effects of the converting enzyme inhibitor enalapril and the angiotensin II receptor antagonist, SC-51316, in a well-characterized model, the cholesterol-fed rabbit. This model has the advantage that both hypercholesterolemia and drug treatment can be initiated simultaneously, thus allowing one to evaluate drug effects during the early stages of lesion development. Enalapril is useful because it blocks the RAS by the same mechanism as captopril ( 17) , although it lacks a sulfhydryl group and the associated antioxidant activity ( 18, 19) . It has also been shown that in normotensive, cholesterol-fed rabbits enalapril has little or no effect on either blood pressure or lipid profiles (20 Atherosclerosis. Animals were killed by pentobarbital injection. Thoracic aortas were rapidly removed, immersion fixed in 10% neutral buffered Formalin, and stained with oil red 0 (0.3%). After a single longitudinal incision along the wall opposite the arterial ostia, the vessels were pinned open for evaluation of the plaque area. The percent plaque coverage was determined from the values for the total area examined and the stained area, by threshold analysis using a true color image analyzer (Videometric 150; American Innovision, Inc., San Diego, CA) interfaced to a color camera (Toshiba 3CCD) mounted on a dissecting microscope. Tissue cholesterol was measured enzymatically as described, after extraction with a chloroform/methanol mixture (2:1 ) according to the method of Folch et al. (26) .
In vitro vascular response. The abdominal aortas were rapidly excised, after injection of sodium pentobarbital, and placed in oxygenated Krebs-bicarbonate buffer. After removal of perivascular tissue, 3-mm ring segments were cut, placed in a 37°C muscle bath containing Krebs-bicarbonate solution, and suspended between two stainless steel wires, one of which was attached to a force transducer (Grass Instrument Co., Quincy, MA). Force changes in response to angiotensin II added to the bath were recorded on a chart recorder (model 8, Grass Instrument Co.). Results
Converting enzyme inhibitor studies. RAS activity in enalaprilmo of treatment, the blood pressure response to bolus injections of angiotensin I was markedly inhibited in the enalapriltreated rabbits at peptide concentrations ranging from 10 to 300 ng/kg (Fig. 1) . Similarly, the serum ACE activity for treated animals was < 8% of the control values at both 1 and 3 mo (Table I) . However, mean arterial pressure after 3 mo of treatment was not significantly affected, as shown in Table I. RAS blockade with enalapril did not affect plasma lipid levels in cholesterol-fed rabbits. As shown in Table II , there were no significant differences between groups for total plasma cholesterol, HDL cholesterol, or plasma triglyceride concentrations after either 1 or 3 mo of treatment.
After 1 mo on the cholesterol diet, the mean value for the percent aortic plaque area was considerably less for the enalapril-treated animals (2.3±0.8%) than for the controls (16.2±6.9%) but, because ofthe variance in the control group, this difference was not statistically significant (P = 0.07; Fig. 2  A) . There was, however, a small but significant difference in the tissue cholesterol concentration after 1 mo. As shown in Fig. 2 B, vessels from treated animals contained 0.7±0.1 mg/g tissue, while vessels from control animals had a cholesterol concentration of 1.3±0.2 mg/g tissue (P < 0.05).
At 3 mo, vessels from the two groups showed an even greater difference in the development ofatherosclerotic lesions, with the percent oflipid stained plaque area being 31.1±8% for the treated animals and 86.8±3.5% for the controls (P < 0.001) (Fig. 3 A) . Aortic cholesterol content was similarly affected by enalapril at 3 mo, with tissues from the treated group having a mean value of 7.4±1.8 mg/g, while the control group had a value of 31.4±3.2 mg/g (P < 0.001; Fig. 3 B) .
Receptor antagonist studies. Preliminary dose-response studies were performed on rabbits to determine a dose of SC-51316 that would be equivalent to enalapril at blocking the RAS. It was found that SC-51316, at a dose of 30 mg/kg, displayed the same oral potency and duration of action as enalapril at 10 mg/kg (Fig. 4) .
Treatment of cholesterol-fed rabbits with SC-51316 at 30 mg/kg per d was found to have no significant effect on body weight, mean arterial pressure, or plasma lipid levels during the course of this study (see Tables III and IV) .
Blockade ofthe RAS after 3 mo was similar to that seen for enalapril, with the pressor response to bolus injections ofangiotensin II being significantly inhibited in treated animals ( Values are means±SEM. n = 10 except for control (n = 6) and treated (n = 8) for mean arterial pressure. * P < 0.001 vs. control. ND, not determined.
5). The vasoconstrictor response to angiotensin II in vitro was also reduced in aortic ring segments from the SC-51316 treated group, shown in Fig. 6 . Treatment with the receptor blocker for 3 mo shifted the EC50 from 3.8±0.6 to 38± 12 nM (P < 0.05, n = 7), while the calculated pD2 was reduced from 8.46±0.08 to 7.54±0.13 (P <0.01, n = 7). After 1 mo on the cholesterol diet, the mean value for the percent aortic plaque area was less for the treated animals (23.8±7%) than for the controls (34.5±6.6%; Fig. 7 A) ; however, this difference was not statistically significant (P = 0.27). Similarly, after 1 mo there was no significant difference between the two groups in the amount of tissue cholesterol extracted from the vessels, with control values having a mean of 1.6±0.5 mg/g, while treated animals had a mean value of 0.8±0.2 mg/g (P = 0.13; Fig. 7 B) .
At 3 mo, vessels from the two groups also showed no significant difference in the development of atherosclerotic lesions, with the percent of lipid stained plaque area being 75.3±7.5% for the controls and 66.4±6.7% for the treated animals (P = 0.39; Fig. 8 A) . Aortic cholesterol content was also not significantly affected by SC-51316 treatment after 3 mo, with control animal tissues having a mean value of 25.1±3.3 mg/g and the treated group having a value of 18.9±3.6 mg/g (P = 0.22; Fig.   8 B) . Values are means±SEM. *P < 0.05. sion, high plasma cholesterol levels, lipoprotein oxidation, and cellular chemotactic and growth factors. Therapies that attenuate atherogenesis usually do so by affecting one or more of these factors. In previously published studies demonstrating reduced plaque formation with captopril therapy, the treated groups also had blood pressure values lower than the controls (5, 6) . Since hypotension, in both humans (8) and experimental animals (9, 10), is associated with decreased atheroma formation, the effects ofcaptopril on blood pressure in these studies could explain the observed reduction in vascular lesions. However, the results reported here show that enalapril treatment, while also significantly attenuating plaque formation, had no effect on conscious blood pressure, thus ruling out hypotension as a possible mechanism for the observed effects of ACE inhibition in this study. In other studies in which antihypertensive drugs have an effect on atherosclerosis, there may also be an effect on lipid metabolism (27) . However, the results reported here (Table II) and by others (28) indicate that ACE inhibitors have no effect on plasma lipid levels. Thus, our results cannot be explained by effects on either blood pressure or plasma lipid levels.
Alternatively, it is possible that the effects of captopril on atherosclerosis may be related to its antioxidant properties. Thus, it has been suggested that the oxidation ofLDL might be inhibited due to captopril's sulfhydryl group, (5, 6) , possibly reducing the formation of vascular lesions (29) . A similar mechanism has been suggested for the effects of probucol and its analogues (30) and the antioxidant butylated hydroxytoluNumerous factors have been implicated in the initiation and development of atherosclerotic plaques, including hyperten- ene ( 31 ) . However, the data presented here show reduced lesions in animals treated with enalapril, which, unlike captopril, is not capable ofinhibiting free radical-induced lipid peroxidation ( 18) or scavenging oxygen-derived free radicals ( 19) , thus indicating that antioxidant activity is not necessary for ACE inhibitors to reduce plaque formation. Similarly, other sulfhydryl-related effects of captopril, such as those observed in cultured endothelial cells (32), also do not necessarily play a role in the attenuation ofatherogenesis by converting enzyme inhibitors.
In an earlier report, no significant effect on atherosclerosis was seen with enalapril treatment of cholesterol-fed rabbits (20) . However, the dose administered was only 0.075-0.1 mg/ kg per d, compared with our treatment protocol with a dose of 10 mg/kg per d. The lower dose used in the earlier study appears to be the most likely reason for the observed lack ofeffect on atherosclerosis.
The importance of cell migration and proliferation in plaque formation is well established (33) . In previous reports showing the efficacy ofcaptopril in reducing atherosclerosis (5, 6) , it was noted that this effect could result from the decrease in angiotensin II levels caused by ACE inhibition, since it has been observed that angiotensin II can be mitogenic in cultured cells (34) and that it can stimulate the synthesis ofgrowth and chemotactic factors (35, 36) . However, the results reported here indicate that blockade of the RAS by the angiotensin II receptor antagonist SC-51316 does not significantly inhibit (Fig. 4) . It was also observed that there was no decline in the receptor-blocking effect of SC-51316 after chronic dosing in cholesterol-fed animals (Fig. 5) angiotensin II receptors, indicating a second mechanism by which this drug can further block the vascular RAS in vivo (Fig. 6 ). This down-regulation presumably occurs in response to high circulating levels of angiotensin 11 (37) , caused by blockade of angiotensin receptors controlling feedback inhibition of renin release (38) .
Since ACE inhibitors block the formation ofangiotensin II, all angiotensin II receptor subtypes are functionally blocked.
However, SC-5 1316 is a specific antagonist for the AT, receptor subtype (21 ). Thus, ifangiotensin II stimulates atherogenesis via a different receptor (e.g., AT2), then ACE inhibitors, but not AT, antagonists, will attenuate lesion development. Although this possibility is consistent with the results described here, it appears to be unlikely in view ofcurrent reports indicating that vascular tissue contains only AT1 receptors (39) .
A more likely explanation for these results is that other peptide hormones, also regulated by ACE, may play a role in suppressing the development of atherosclerosis. For example, the activity of the vasoactive hormone bradykinin is potentiated in the presence ofACE inhibitors (40) . Increased bradykinin activity can stimulate endothelial cell production ofprostacyclin or endothelium-derived relaxing factor/nitric oxide (41) , which could inhibit platelet activation (42, 43) and monocyte adhesion or chemotaxis (44) at plaque sites, potentially attenuating lesion formation (45, 46) . Consistent with this mechanism is the report that in vivo platelet activity is significantly reduced in hypertensive patients receiving ACE inhibitors but not other standard antihypertensive therapies (47) . A role for kinins in mediating the effect ofACE inhibitors on vascular lesions is also supported by the report that a brady- kinin receptor antagonist (HOE 140) can suppress the attenuation of vascular lesions by ramipril, after arterial injury in rats by balloon angioplasty (48) .
Such speculations notwithstanding, it does not appear that a reduction in angiotensin II can be the primary mechanism by which ACE inhibitors attenuate atherogenesis. Instead it is suggested that other peptide hormones may be important. Thus, in the absence of effects on systemic blood pressure or changes in plasma lipids, it appears that an ACE-dependent factor can reduce the progression ofatherosclerosis, probably by modulating the effects that high plasma cholesterol levels have on cellular elements involved in the early stages of plaque formation. Further characterization of this mechanism may provide new leads in the development of unique therapies for treating atherosclerosis and its clinical sequelae. 
